ZHEJIANG ZHENYUAN(SZ:000705)2022-12-08 05:16Group 1: Product Launch and Sales Strategy - The company has obtained new drug certification and registration for adenosylmethionine, aiming for a quick market acceptance due to its familiarity among doctors [1] - Future sales strategy for adenosylmethionine will focus on agency-based marketing [2] - Sales of methadone series products showed significant year-on-year growth, but further academic promotion and bidding work are necessary for increased volume [2] Group 2: Sales Performance and Challenges - In the first half of the year, the company achieved sales of 80.93 million yuan for formulations, a slight decline attributed to the new GMP certification process for injection products [3] - Raw material sales reached 86.37 million yuan, showing a decrease due to price fluctuations in upstream raw materials [3] - The company’s traditional Chinese medicine (TCM) sales reached 67.11 million yuan, with a year-on-year increase, despite challenges from GMP re-certification [4] Group 3: Future Development and Market Expansion - The company plans to enhance the quality of TCM products in response to increasing consumer demands and regulatory standards [4] - The health industry development strategy includes expanding into maternal and infant care services, oral health services, and health management [5] - The company is actively seeking suitable acquisition targets related to its main business, such as traditional Chinese medicine production enterprises [5] Group 4: Research and Development - The company’s research center focuses on microbial fermentation and synthetic pharmaceutical engineering, with plans to develop new drugs targeting antifungal and digestive system treatments [5] - Ongoing research projects are progressing as planned, with a focus on leveraging various R&D resources [5]